|
|
Office Locations:
|
One Broadway, 14th Floor
Cambridge, MA 02142
Phone: 203-791-6808
| |
|
|
|
|
|
|
Life Sciences & Healthcare
|
|
|
|
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. The Boehringer Ingelheim Venture Fund's mission is to invest in the development of pioneering science -- from idea to proof of concept -- which offer the potential to provide significant benefits firstly for patients and also for Boehringer Ingelheim's business. Fund's total fund volume is €300 million. Opening investments of up to EURO2 million per venture will be made at the early stage with subsequent staged investments made to align with each venture's progress, up to EURO15 million per venture over its life. The Boehringer Ingelheim Venture Fund intends to invest in groundbreaking therapeutic approaches and technologies that have the potential to advance patient care and meet unmet medical needs.
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
| COMPANY STAGE | REVENUE |
| Venture Capital | |
Seed Stage
(includes "pre-seed," or
concept stage) | No Revenue |
| Early Stage | Minimal
Revenue |
Growth Stage
(also called Mid-stage) | $2M-$7M |
Expansion Stage
(also called Late-stage) | $7M and greater |
| Private Equity | |
| Lower Middle Market | $10M-$249M |
| Middle Market | $250M-$499M |
| Upper Middle Market | $500M-$1B |
| Large Cap | >$1B |
|
|
|
|
|
